John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Management of ulcerative colitis with 5-aminosalicylates failure Volume 28, supplement 5, November 2021

Figures

  • Figure 1
  • Figure 2
Author
CHU d’Amiens and PeriTox, Université de Picardie, Service d’hépato-gastroentérologie, Rond point du Cabrol, 80054 Amiens
* Correspondance

While the majority of patients with ulcerative colitis (UC) are treated with 5-aminosalicylates (5-ASA), at least one third will experience treatment failure. Recent publications have changed the therapeutic approach to this frequent clinical situation, which is based initially on: (i) objective confirmation of the presence of an active disease, (ii) therapeutic compliance evaluation, and (iii) dose and mode of 5-ASA administration reevaluation. In case of failure, the strategy is based on the response to corticosteroids, the severity of the disease but also the reimbursement parameters of the various molecules available such as azathioprine, anti-TNFs (infliximab, adalimumab, and golimumab) and vedolizumab.